Welcome to our dedicated page for ACHIEVE LIFE SCIENCES SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Achieve Life Sciences (ACHV) reported that it furnished, not filed, a press release announcing its financial results for the third quarter ended September 30, 2025. The company submitted the press release as Exhibit 99.1 to an Item 2.02 Form 8-K dated November 6, 2025.
The furnishing designation means the information is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Achieve Life Sciences (ACHV) filed an initial statement of beneficial ownership (Form 3) for its Chief Legal Officer. The reporting person indicated no securities beneficially owned (0).
The event date for this filing is 10/20/2025. The form was filed by one reporting person, reflecting the officer’s status and current holdings at the time of the event.
Achieve Life Sciences, Inc. reports that it has finalized separation terms with Dr. Cindy Jacobs, who previously informed the board she would resign as Chief Medical Officer and President effective October 6, 2025. On that date, the company and Dr. Jacobs entered into a Separation Agreement and a related Consulting Agreement.
Under these agreements, Dr. Jacobs will continue to provide consulting services until the first business day after U.S. Food and Drug Administration approval of the company’s New Drug Application for cytisinicline. During this consulting period, her existing equity awards will continue to vest. She will receive a lump-sum cash severance of $101,296, accelerated vesting of the unvested portions of her January 2023 and January 2024 time-based stock options upon the end of her consultancy at or after NDA approval, and an extension of the exercise period for those options to 12 months after that termination. The company will also reimburse up to $10,000 in legal fees related to these agreements.
Achieve Life Sciences, Inc. (ACHV) reported an insider acquisition: Chief Operations Officer Craig Donnelly was granted a stock option on 10/01/2025 to purchase 50,000 shares of common stock at a $3.10 exercise price. The option vests with 1/4 of the award on the first anniversary of September 8, 2025 and then in substantially equal monthly installments over the following 36 months, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents a routine executive equity award that creates potential future dilution if exercised and ties the officer’s compensation to company share performance.
Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported insider transactions on 09/18/2025. The filing shows settlement of 168,000 performance restricted stock units (PRSUs) into common stock, increasing his beneficial ownership to 178,000 shares immediately after settlement. Concurrently, the reporting person sold 50,060 shares in multiple transactions at a weighted average price of $2.92 per share (individual sale prices ranged from $2.83 to $3.02), reducing beneficial ownership to 127,940 shares. The PRSUs each represent a contingent right to one share and vest upon achievement of specified milestones; the related PRSUs list a date of 12/06/2028 in the filing. The sale is disclosed as made to satisfy income tax withholding and remittance obligations in connection with net settlement.
On September 18, 2025, Achieve Life Sciences CEO Stewart Richard Alistair settled performance restricted stock units into 297,500 shares of common stock and sold 129,501 shares at a weighted average price of $2.92 per share in transactions ranging from $2.83 to $3.02. After these transactions he holds 228,875 shares directly, plus 359 shares held by his spouse and 882 shares held through Ricanto Limited. Footnotes state that PRSUs each convert into one share upon milestone-based vesting and that some shares were sold to cover tax withholding on net settlement.
Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards. One option covers 25,000 shares exercisable beginning 03/14/2033 at $4.53; the other covers 22,500 shares exercisable beginning 01/22/2034 at $4.55. Vesting schedules for each grant are disclosed in the filing.
Achieve Life Sciences, Inc. reported that Dr. Cindy Jacobs has chosen to resign from her roles as Chief Medical Officer and President, effective October 6, 2025. She informed the board on September 5, 2025. The company is negotiating a consulting agreement so Dr. Jacobs can continue providing advisory services after her departure.
Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported receipt of 168,000 performance restricted stock units (PRSUs) on 09/04/2025. The filing states these PRSUs were previously disclosed on December 9, 2024 and were earned after the Compensation Committee certified achievement of specified performance criteria. Each PRSU converts into one share of common stock at settlement. The reported award shows an exercise/settlement reference date of 12/06/2028 and a reported price of $0. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Oki on 09/08/2025.
Richard Stewart, a director and executive officer of Achieve Life Sciences, Inc. (ACHV), reported two awards of Performance Restricted Stock Units (PRSUs) on 09/04/2025. The filing shows acquisition of 140,000 PRSUs (linked to common stock) and 157,500 PRSUs, each representing a contingent right to one share at settlement. The PRSUs were previously reported as earned when performance targets were certified by the Compensation Committee. The awards list future settlement/exercise dates of 01/22/2028 and 01/13/2029 and show 0 shares beneficially owned following the transactions, indicating these remain contingent/subject to settlement terms.